nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—SLC2A1—ovarian cancer	0.86	1	CbGaD
Etomidate—CYP19A1—Paclitaxel—ovarian cancer	0.0234	1	CbGbCtD
Etomidate—CYP19A1—follicular fluid—ovarian cancer	0.0199	0.268	CbGeAlD
Etomidate—CYP19A1—corpus luteum—ovarian cancer	0.0115	0.154	CbGeAlD
Etomidate—CYP19A1—ovarian follicle—ovarian cancer	0.00896	0.121	CbGeAlD
Etomidate—SLC2A1—embryo—ovarian cancer	0.00383	0.0516	CbGeAlD
Etomidate—SLC2A1—epithelium—ovarian cancer	0.00313	0.0421	CbGeAlD
Etomidate—SLC2A1—decidua—ovarian cancer	0.00295	0.0398	CbGeAlD
Etomidate—SLC2A1—gonad—ovarian cancer	0.0026	0.035	CbGeAlD
Etomidate—SLC2A1—uterus—ovarian cancer	0.00258	0.0348	CbGeAlD
Etomidate—SLC2A1—female reproductive system—ovarian cancer	0.00232	0.0313	CbGeAlD
Etomidate—SLC2A1—bone marrow—ovarian cancer	0.00219	0.0296	CbGeAlD
Etomidate—SLC2A1—female gonad—ovarian cancer	0.00211	0.0285	CbGeAlD
Etomidate—SLC2A1—vagina—ovarian cancer	0.0021	0.0283	CbGeAlD
Etomidate—SLC2A1—testis—ovarian cancer	0.00187	0.0253	CbGeAlD
Etomidate—Pseudoephedrine—IL2—ovarian cancer	0.00154	1	CrCbGaD
Etomidate—SLC2A1—lymph node—ovarian cancer	0.00136	0.0183	CbGeAlD
Etomidate—CYP11B2—lymph node—ovarian cancer	0.00116	0.0157	CbGeAlD
Etomidate—CYP19A1—endometrium—ovarian cancer	0.000886	0.0119	CbGeAlD
Etomidate—CYP19A1—gonad—ovarian cancer	0.000822	0.0111	CbGeAlD
Etomidate—CYP19A1—uterus—ovarian cancer	0.000817	0.011	CbGeAlD
Etomidate—CYP19A1—female reproductive system—ovarian cancer	0.000734	0.0099	CbGeAlD
Etomidate—GABRB2—testis—ovarian cancer	0.000731	0.00985	CbGeAlD
Etomidate—CYP19A1—female gonad—ovarian cancer	0.000668	0.00901	CbGeAlD
Etomidate—CYP19A1—testis—ovarian cancer	0.000592	0.00799	CbGeAlD
Etomidate—CYP19A1—lymph node—ovarian cancer	0.000429	0.00579	CbGeAlD
Etomidate—Hypoxia—Vinorelbine—ovarian cancer	9.08e-05	0.0729	CcSEcCtD
Etomidate—Convulsion—Altretamine—ovarian cancer	8.08e-05	0.0648	CcSEcCtD
Etomidate—Respiratory failure—Topotecan—ovarian cancer	6.87e-05	0.0551	CcSEcCtD
Etomidate—SLC2A1—Metabolism—CYP1B1—ovarian cancer	6.44e-05	0.00163	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—AKT1—ovarian cancer	6.34e-05	0.00161	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	6.33e-05	0.0016	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	6.14e-05	0.00156	CbGpPWpGaD
Etomidate—Respiratory failure—Vinorelbine—ovarian cancer	5.88e-05	0.0472	CcSEcCtD
Etomidate—CYP19A1—Metabolism—NME2—ovarian cancer	5.86e-05	0.00149	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	5.83e-05	0.00148	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PPP1CC—ovarian cancer	5.83e-05	0.00148	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—BRIP1—ovarian cancer	5.83e-05	0.00148	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PPP2R1A—ovarian cancer	5.71e-05	0.00145	CbGpPWpGaD
Etomidate—SLC2A1—Disease—TERT—ovarian cancer	5.42e-05	0.00137	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	5.37e-05	0.00136	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—ABCB1—ovarian cancer	5.3e-05	0.00134	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—TYMS—ovarian cancer	5.21e-05	0.00132	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CAV1—ovarian cancer	5.01e-05	0.00127	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.97e-05	0.00126	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.93e-05	0.00125	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	4.85e-05	0.00123	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HSD17B6—ovarian cancer	4.84e-05	0.00123	CbGpPWpGaD
Etomidate—Vomiting—Altretamine—ovarian cancer	4.84e-05	0.0388	CcSEcCtD
Etomidate—SLC2A1—Disease—IL6ST—ovarian cancer	4.75e-05	0.0012	CbGpPWpGaD
Etomidate—SLC2A1—Disease—APC—ovarian cancer	4.56e-05	0.00116	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—YAP1—ovarian cancer	4.54e-05	0.00115	CbGpPWpGaD
Etomidate—Pain—Carboplatin—ovarian cancer	4.49e-05	0.0361	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—SPARC—ovarian cancer	4.49e-05	0.00114	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.49e-05	0.00114	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.48e-05	0.00113	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	4.47e-05	0.00113	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	4.35e-05	0.0011	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.33e-05	0.0011	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	4.3e-05	0.00109	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	4.29e-05	0.00109	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.28e-05	0.00108	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.25e-05	0.00108	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	4.22e-05	0.00107	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CAV1—ovarian cancer	4.2e-05	0.00106	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	4.2e-05	0.00106	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DLC1—ovarian cancer	4.12e-05	0.00104	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	4.11e-05	0.00104	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.1e-05	0.00104	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.05e-05	0.00103	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PIK3CD—ovarian cancer	4.01e-05	0.00102	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	3.96e-05	0.001	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.96e-05	0.001	CbGpPWpGaD
Etomidate—Respiratory failure—Paclitaxel—ovarian cancer	3.95e-05	0.0317	CcSEcCtD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.95e-05	0.001	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.91e-05	0.000992	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—YAP1—ovarian cancer	3.91e-05	0.00099	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.87e-05	0.00098	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CG—ovarian cancer	3.82e-05	0.000968	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	3.79e-05	0.00096	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYTB—ovarian cancer	3.78e-05	0.000957	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	3.71e-05	0.000939	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—FASN—ovarian cancer	3.7e-05	0.000937	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.69e-05	0.000935	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—SLC5A5—ovarian cancer	3.64e-05	0.000921	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.58e-05	0.000907	CbGpPWpGaD
Etomidate—SLC2A1—Disease—ERBB2—ovarian cancer	3.54e-05	0.000898	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—SLC2A1—ovarian cancer	3.51e-05	0.00089	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PIK3CB—ovarian cancer	3.5e-05	0.000886	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MTOR—ovarian cancer	3.5e-05	0.000886	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	3.49e-05	0.000883	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	3.49e-05	0.000883	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.46e-05	0.000876	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.44e-05	0.000871	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.44e-05	0.00087	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.42e-05	0.000867	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.42e-05	0.000865	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	3.41e-05	0.000864	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	3.41e-05	0.000864	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.4e-05	0.000861	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP1B1—ovarian cancer	3.37e-05	0.000853	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CD—ovarian cancer	3.36e-05	0.000851	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—BCL9—ovarian cancer	3.35e-05	0.00085	CbGpPWpGaD
Etomidate—Respiratory failure—Docetaxel—ovarian cancer	3.35e-05	0.0269	CcSEcCtD
Etomidate—CYP19A1—Metabolism—PPP1CC—ovarian cancer	3.3e-05	0.000837	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—BRIP1—ovarian cancer	3.3e-05	0.000837	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CDKN1B—ovarian cancer	3.28e-05	0.000831	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—SOD1—ovarian cancer	3.26e-05	0.000827	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PPP2R1A—ovarian cancer	3.25e-05	0.000823	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	3.23e-05	0.000819	CbGpPWpGaD
Etomidate—Hyperventilation—Epirubicin—ovarian cancer	3.22e-05	0.0259	CcSEcCtD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	3.22e-05	0.000816	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.22e-05	0.000815	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—FASN—ovarian cancer	3.19e-05	0.000807	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.14e-05	0.000796	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—SLC5A5—ovarian cancer	3.13e-05	0.000794	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.12e-05	0.000791	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CTNNB1—ovarian cancer	3.1e-05	0.000785	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—SLC2A1—ovarian cancer	3.03e-05	0.000767	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PTEN—ovarian cancer	3.02e-05	0.000766	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PPP2R1A—ovarian cancer	2.99e-05	0.000757	CbGpPWpGaD
Etomidate—Hyperventilation—Doxorubicin—ovarian cancer	2.98e-05	0.0239	CcSEcCtD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.97e-05	0.000753	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.97e-05	0.000752	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.96e-05	0.000751	CbGpPWpGaD
Etomidate—Arrhythmia—Melphalan—ovarian cancer	2.96e-05	0.0238	CcSEcCtD
Etomidate—ADRA2B—G alpha (i) signalling events—CXCL8—ovarian cancer	2.96e-05	0.000749	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.94e-05	0.000745	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CB—ovarian cancer	2.93e-05	0.000742	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CYP1B1—ovarian cancer	2.9e-05	0.000735	CbGpPWpGaD
Etomidate—Convulsion—Chlorambucil—ovarian cancer	2.87e-05	0.023	CcSEcCtD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	2.86e-05	0.000725	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ABCB1—ovarian cancer	2.77e-05	0.000702	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.75e-05	0.000696	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.73e-05	0.000692	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—TYMS—ovarian cancer	2.72e-05	0.00069	CbGpPWpGaD
Etomidate—SLC2A1—Disease—STAT3—ovarian cancer	2.7e-05	0.000685	CbGpPWpGaD
Etomidate—SLC2A1—Disease—NRAS—ovarian cancer	2.7e-05	0.000683	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DOK1—ovarian cancer	2.65e-05	0.000672	CbGpPWpGaD
Etomidate—Arrhythmia—Vinorelbine—ovarian cancer	2.59e-05	0.0208	CcSEcCtD
Etomidate—GABRB2—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.58e-05	0.000654	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MAPK3—ovarian cancer	2.58e-05	0.000654	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PPP2R1A—ovarian cancer	2.57e-05	0.000652	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.57e-05	0.000652	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.56e-05	0.000649	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PTEN—ovarian cancer	2.53e-05	0.000641	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	2.52e-05	0.000639	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MYC—ovarian cancer	2.51e-05	0.000636	CbGpPWpGaD
Etomidate—Convulsion—Melphalan—ovarian cancer	2.5e-05	0.0201	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—PPP1CC—ovarian cancer	2.49e-05	0.000632	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—MAPK1—ovarian cancer	2.47e-05	0.000624	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MAPK1—ovarian cancer	2.46e-05	0.000622	CbGpPWpGaD
Etomidate—SLC2A1—Disease—EGFR—ovarian cancer	2.46e-05	0.000622	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.42e-05	0.000612	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—IL6—ovarian cancer	2.41e-05	0.000611	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.41e-05	0.00061	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ABCB1—ovarian cancer	2.39e-05	0.000605	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—CAV1—ovarian cancer	2.39e-05	0.000605	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.39e-05	0.000604	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.36e-05	0.000598	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	2.35e-05	0.000595	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—TYMS—ovarian cancer	2.35e-05	0.000595	CbGpPWpGaD
Etomidate—SLC2A1—Disease—KRAS—ovarian cancer	2.32e-05	0.000588	CbGpPWpGaD
Etomidate—Pain—Chlorambucil—ovarian cancer	2.31e-05	0.0186	CcSEcCtD
Etomidate—Tachycardia—Melphalan—ovarian cancer	2.3e-05	0.0185	CcSEcCtD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	2.27e-05	0.000575	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—MAPK1—ovarian cancer	2.25e-05	0.000571	CbGpPWpGaD
Etomidate—Hiccups—Epirubicin—ovarian cancer	2.22e-05	0.0178	CcSEcCtD
Etomidate—CYP19A1—Metabolism—YAP1—ovarian cancer	2.22e-05	0.000561	CbGpPWpGaD
Etomidate—Hypotension—Melphalan—ovarian cancer	2.2e-05	0.0177	CcSEcCtD
Etomidate—CYP11B2—Metabolism—CAV1—ovarian cancer	2.19e-05	0.000556	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.19e-05	0.000555	CbGpPWpGaD
Etomidate—Hypertension—Vinorelbine—ovarian cancer	2.18e-05	0.0175	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—PIK3CG—ovarian cancer	2.17e-05	0.000551	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PIK3CA—ovarian cancer	2.13e-05	0.00054	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.1e-05	0.000531	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.07e-05	0.000523	CbGpPWpGaD
Etomidate—Pain—Topotecan—ovarian cancer	2.06e-05	0.0165	CcSEcCtD
Etomidate—Hiccups—Doxorubicin—ovarian cancer	2.05e-05	0.0165	CcSEcCtD
Etomidate—Pain—Melphalan—ovarian cancer	2.02e-05	0.0162	CcSEcCtD
Etomidate—Tachycardia—Vinorelbine—ovarian cancer	2.01e-05	0.0161	CcSEcCtD
Etomidate—CYP11B2—Metabolism—PIK3CG—ovarian cancer	2e-05	0.000506	CbGpPWpGaD
Etomidate—Bradycardia—Paclitaxel—ovarian cancer	1.98e-05	0.0159	CcSEcCtD
Etomidate—GABRB2—Neuronal System—HRAS—ovarian cancer	1.98e-05	0.000501	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HRAS—ovarian cancer	1.97e-05	0.0005	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—MAPK1—ovarian cancer	1.97e-05	0.000499	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.97e-05	0.000499	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.93e-05	0.000488	CbGpPWpGaD
Etomidate—Hypotension—Vinorelbine—ovarian cancer	1.92e-05	0.0154	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—PIK3CD—ovarian cancer	1.91e-05	0.000484	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CAV1—ovarian cancer	1.89e-05	0.000479	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HDAC6—ovarian cancer	1.89e-05	0.000479	CbGpPWpGaD
Etomidate—SLC2A1—Disease—IL6—ovarian cancer	1.89e-05	0.000478	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PPP2R1A—ovarian cancer	1.86e-05	0.000472	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—HRAS—ovarian cancer	1.81e-05	0.000459	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.81e-05	0.000458	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—FASN—ovarian cancer	1.81e-05	0.000457	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CXCL8—ovarian cancer	1.79e-05	0.000453	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CA—ovarian cancer	1.79e-05	0.000452	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—SLC5A5—ovarian cancer	1.78e-05	0.00045	CbGpPWpGaD
Etomidate—Pain—Vinorelbine—ovarian cancer	1.76e-05	0.0141	CcSEcCtD
Etomidate—CYP11B2—Metabolism—PIK3CD—ovarian cancer	1.76e-05	0.000445	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKT1—ovarian cancer	1.74e-05	0.000441	CbGpPWpGaD
Etomidate—Arrhythmia—Paclitaxel—ovarian cancer	1.74e-05	0.014	CcSEcCtD
Etomidate—CYP11B1—Metabolism—PIK3CG—ovarian cancer	1.72e-05	0.000436	CbGpPWpGaD
Etomidate—Vomiting—Chlorambucil—ovarian cancer	1.72e-05	0.0138	CcSEcCtD
Etomidate—CYP19A1—Metabolism—SLC2A1—ovarian cancer	1.72e-05	0.000435	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.68e-05	0.000425	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—YAP1—ovarian cancer	1.67e-05	0.000424	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CB—ovarian cancer	1.67e-05	0.000422	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP1B1—ovarian cancer	1.64e-05	0.000417	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—XIAP—ovarian cancer	1.64e-05	0.000415	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.61e-05	0.000408	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SMARCA4—ovarian cancer	1.6e-05	0.000404	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—HRAS—ovarian cancer	1.58e-05	0.000401	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EREG—ovarian cancer	1.56e-05	0.000395	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CB—ovarian cancer	1.53e-05	0.000388	CbGpPWpGaD
Etomidate—Vomiting—Topotecan—ovarian cancer	1.53e-05	0.0123	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—IL2—ovarian cancer	1.53e-05	0.000388	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CD—ovarian cancer	1.51e-05	0.000384	CbGpPWpGaD
Etomidate—Vomiting—Melphalan—ovarian cancer	1.5e-05	0.012	CcSEcCtD
Etomidate—Arrhythmia—Docetaxel—ovarian cancer	1.48e-05	0.0118	CcSEcCtD
Etomidate—Convulsion—Paclitaxel—ovarian cancer	1.47e-05	0.0118	CcSEcCtD
Etomidate—Hypertension—Paclitaxel—ovarian cancer	1.46e-05	0.0118	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—PGR—ovarian cancer	1.46e-05	0.00037	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	1.46e-05	0.000369	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKT1—ovarian cancer	1.46e-05	0.000369	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.45e-05	0.000368	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CG—ovarian cancer	1.37e-05	0.000348	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PARP1—ovarian cancer	1.36e-05	0.000344	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCB1—ovarian cancer	1.35e-05	0.000343	CbGpPWpGaD
Etomidate—Tachycardia—Paclitaxel—ovarian cancer	1.35e-05	0.0108	CcSEcCtD
Etomidate—CYP19A1—Metabolism—TYMS—ovarian cancer	1.33e-05	0.000337	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTEN—ovarian cancer	1.32e-05	0.000335	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CB—ovarian cancer	1.32e-05	0.000334	CbGpPWpGaD
Etomidate—Vomiting—Vinorelbine—ovarian cancer	1.31e-05	0.0105	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—VEGFA—ovarian cancer	1.3e-05	0.000329	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6ST—ovarian cancer	1.3e-05	0.000329	CbGpPWpGaD
Etomidate—Hypotension—Paclitaxel—ovarian cancer	1.29e-05	0.0104	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—NRAS—ovarian cancer	1.28e-05	0.000325	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CG—ovarian cancer	1.25e-05	0.000316	CbGpPWpGaD
Etomidate—Convulsion—Docetaxel—ovarian cancer	1.25e-05	0.01	CcSEcCtD
Etomidate—Hypertension—Docetaxel—ovarian cancer	1.24e-05	0.00997	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—MAPK3—ovarian cancer	1.23e-05	0.000312	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CD—ovarian cancer	1.21e-05	0.000306	CbGpPWpGaD
Etomidate—Pain—Paclitaxel—ovarian cancer	1.18e-05	0.0095	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—MAPK1—ovarian cancer	1.17e-05	0.000296	CbGpPWpGaD
Etomidate—Tachycardia—Docetaxel—ovarian cancer	1.15e-05	0.00919	CcSEcCtD
Etomidate—CYP11B1—Metabolism—PTEN—ovarian cancer	1.14e-05	0.000289	CbGpPWpGaD
Etomidate—Bradycardia—Epirubicin—ovarian cancer	1.13e-05	0.00911	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—KRAS—ovarian cancer	1.11e-05	0.00028	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PPP2R1A—ovarian cancer	1.1e-05	0.000279	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CD—ovarian cancer	1.1e-05	0.000278	CbGpPWpGaD
Etomidate—Hypotension—Docetaxel—ovarian cancer	1.1e-05	0.0088	CcSEcCtD
Etomidate—CYP19A1—Metabolism—CAV1—ovarian cancer	1.07e-05	0.000271	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CB—ovarian cancer	1.05e-05	0.000267	CbGpPWpGaD
Etomidate—Bradycardia—Doxorubicin—ovarian cancer	1.05e-05	0.00843	CcSEcCtD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.02e-05	0.000259	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CA—ovarian cancer	1.02e-05	0.000257	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CXCL8—ovarian cancer	1.01e-05	0.000256	CbGpPWpGaD
Etomidate—Pain—Docetaxel—ovarian cancer	1e-05	0.00806	CcSEcCtD
Etomidate—Arrhythmia—Epirubicin—ovarian cancer	9.95e-06	0.00799	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—TP53—ovarian cancer	9.82e-06	0.000249	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CG—ovarian cancer	9.76e-06	0.000247	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—IL2—ovarian cancer	9.67e-06	0.000245	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CB—ovarian cancer	9.56e-06	0.000242	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—HRAS—ovarian cancer	9.4e-06	0.000238	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CA—ovarian cancer	9.34e-06	0.000237	CbGpPWpGaD
Etomidate—Arrhythmia—Doxorubicin—ovarian cancer	9.21e-06	0.00739	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—CXCL8—ovarian cancer	9.19e-06	0.000233	CbGpPWpGaD
Etomidate—Vomiting—Paclitaxel—ovarian cancer	8.8e-06	0.00707	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—IL2—ovarian cancer	8.78e-06	0.000222	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TERT—ovarian cancer	8.75e-06	0.000222	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CD—ovarian cancer	8.58e-06	0.000217	CbGpPWpGaD
Etomidate—Convulsion—Epirubicin—ovarian cancer	8.4e-06	0.00675	CcSEcCtD
Etomidate—Hypertension—Epirubicin—ovarian cancer	8.38e-06	0.00672	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—AKT1—ovarian cancer	8.3e-06	0.00021	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CAV1—ovarian cancer	8.09e-06	0.000205	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CA—ovarian cancer	8.05e-06	0.000204	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ESR1—ovarian cancer	7.8e-06	0.000197	CbGpPWpGaD
Etomidate—Convulsion—Doxorubicin—ovarian cancer	7.78e-06	0.00624	CcSEcCtD
Etomidate—Hypertension—Doxorubicin—ovarian cancer	7.75e-06	0.00622	CcSEcCtD
Etomidate—Tachycardia—Epirubicin—ovarian cancer	7.73e-06	0.0062	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—IL6ST—ovarian cancer	7.67e-06	0.000194	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—AKT1—ovarian cancer	7.63e-06	0.000193	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CB—ovarian cancer	7.48e-06	0.000189	CbGpPWpGaD
Etomidate—Vomiting—Docetaxel—ovarian cancer	7.46e-06	0.00599	CcSEcCtD
Etomidate—Hypotension—Epirubicin—ovarian cancer	7.4e-06	0.00594	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—APC—ovarian cancer	7.37e-06	0.000187	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CG—ovarian cancer	7.37e-06	0.000187	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—NRAS—ovarian cancer	7.37e-06	0.000187	CbGpPWpGaD
Etomidate—Tachycardia—Doxorubicin—ovarian cancer	7.15e-06	0.00574	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—MAPK3—ovarian cancer	7.06e-06	0.000179	CbGpPWpGaD
Etomidate—Hypotension—Doxorubicin—ovarian cancer	6.85e-06	0.00549	CcSEcCtD
Etomidate—Pain—Epirubicin—ovarian cancer	6.77e-06	0.00543	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—MAPK1—ovarian cancer	6.72e-06	0.00017	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—EGFR—ovarian cancer	6.71e-06	0.00017	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKT1—ovarian cancer	6.57e-06	0.000167	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CD—ovarian cancer	6.48e-06	0.000164	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PTEN—ovarian cancer	6.46e-06	0.000164	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CA—ovarian cancer	6.42e-06	0.000163	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—KRAS—ovarian cancer	6.34e-06	0.000161	CbGpPWpGaD
Etomidate—Pain—Doxorubicin—ovarian cancer	6.26e-06	0.00503	CcSEcCtD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CA—ovarian cancer	5.83e-06	0.000148	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	5.72e-06	0.000145	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	5.65e-06	0.000143	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	5.65e-06	0.000143	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	5.43e-06	0.000137	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	5.39e-06	0.000137	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	5.3e-06	0.000134	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	5.24e-06	0.000133	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	5.19e-06	0.000132	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL2—ovarian cancer	5.19e-06	0.000131	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	5.16e-06	0.000131	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	5.06e-06	0.000128	CbGpPWpGaD
Etomidate—Vomiting—Epirubicin—ovarian cancer	5.03e-06	0.00404	CcSEcCtD
Etomidate—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	5.01e-06	0.000127	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	4.91e-06	0.000124	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	4.88e-06	0.000124	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	4.76e-06	0.000121	CbGpPWpGaD
Etomidate—Vomiting—Doxorubicin—ovarian cancer	4.66e-06	0.00374	CcSEcCtD
Etomidate—CYP19A1—Metabolism—PIK3CA—ovarian cancer	4.56e-06	0.000116	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	4.41e-06	0.000112	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	4.36e-06	0.000111	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	4.35e-06	0.00011	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	4.17e-06	0.000106	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MYC—ovarian cancer	4.06e-06	0.000103	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	3.97e-06	0.0001	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	3.97e-06	0.0001	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	3.75e-06	9.49e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKT1—ovarian cancer	3.73e-06	9.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	3.44e-06	8.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—ovarian cancer	3.33e-06	8.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	3.19e-06	8.07e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6—ovarian cancer	3.05e-06	7.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	2.81e-06	7.12e-05	CbGpPWpGaD
